BioLargo rides PFAS wave as tech, funding, and partnerships align

BioLargo's proprietary Aqueous Electrostatic Concentrator (AEC) technology has proven its commercial viability through a landmark installation at Lake Stockholm, New Jersey, where it has removed over 99% of PFAS contaminants from more than two million gallons of drinking water over six months. This real-world success, validated by third-party monitoring, provides a compelling reference for utility engineers and regulators seeking reliable, scalable PFAS remediation solutions, as emphasized by Tonya Chandler, President of BioLargo Equipment Solutions & Technologies.

The AEC technology distinguishes itself from conventional PFAS treatment methods by eliminating the need for granular activated carbon or single-use ion exchange resins, thereby addressing persistent challenges such as capturing short-chain PFAS compounds and reducing operational costs. Its innovative collection mechanism generates significantly less contaminated waste, which has translated into lower hazardous waste disposal expenses for the Lake Stockholm facility, marking a sustainable and cost-effective advancement in PFAS remediation.

Building on the proven success at Lake Stockholm, BioLargo is strategically leveraging this installation as a launch pad for broader applications of the AEC technology beyond municipal drinking water. Through partnerships like the memorandum of understanding with Aquatech, BioLargo aims to integrate the AEC with complementary PFAS treatment and destruction technologies to tackle industrial wastewater, landfill leachate, and groundwater contamination, as highlighted by CEO Dennis P. Calvert.

By early 2026, BioLargo and Aquatech forged a pivotal global partnership to accelerate the commercialization and deployment of PFAS water treatment solutions by integrating BioLargo’s proprietary Aqueous Electrostatic Concentrator (AEC) technology into Aquatech’s award-winning water purification systems. Leveraging Aquatech’s comprehensive portfolio—including membrane, thermal, biological, and electrochemical treatments—and its recognition as the 2025 Water Technology Company of the Year, this alliance aims to enhance scalability and regulatory compliance, targeting municipal, industrial, and government clients worldwide to fast-track effective PFAS remediation.

In mid-2026, BioLargo strategically deepened its industry influence by joining the New Jersey PFAS Partnership Innovation Consortium (NJ PFAS-PIC), a multi-institutional collaboration that accelerates technology validation and deployment through shared expertise. With its patented AEC technology already proven in real-world conditions at the Lake Stockholm municipal water facility, BioLargo’s President of Equipment Solutions & Technologies, Tonya Chandler, was appointed to the consortium’s Board of Directors, positioning the company alongside NJIT, Princeton, Rutgers, Stevens, NJDEP, and major utilities to shape PFAS remediation efforts and address regulatory and technological challenges—particularly targeting difficult short-chain and ultra-short-chain PFAS compounds to expand market impact.

By mid-2026, the EPA unveiled a sweeping overhaul of its PFAS strategy, committing nearly $1 billion in grants aimed at aiding states and disadvantaged communities in reducing PFAS exposure in drinking water. This comprehensive approach targets the full lifecycle of PFAS contamination through a combination of drinking water regulations, industrial discharge controls, advanced treatment technologies, and long-term monitoring, while proposed rules seek to preserve federal limits for PFOA and PFOS with extended compliance deadlines to 2031, ensuring regulatory durability and practical implementation.

Complementing federal regulatory efforts, BioLargo’s engineering subsidiary BLEST secured $1.4 million in contract renewals to provide critical air quality and environmental compliance services at five U.S. Air Force bases across New Mexico and Arizona. These contracts underscore BioLargo’s strategic alignment with government initiatives by delivering essential regulatory support on multi-year military projects, offering stable, repeatable revenue streams that bolster the company’s capacity to scale its cleantech and PFAS-focused innovations in tandem with evolving federal investments.

The EPA’s dual focus on health-protective and legally durable PFAS regulations, combined with billions in federal investments toward water infrastructure improvements, creates a pivotal opportunity for scaling innovative PFAS solutions. As public awareness grows and regulatory frameworks solidify, companies like BioLargo are well-positioned to leverage this critical window to advance sustainable PFAS management technologies and meet expanding government demand for contamination control at the source.

By mid-2026, BioLargo demonstrated a clear commitment to aligning executive incentives with shareholder interests, as evidenced by the CEO’s acceptance of equity compensation locked until the company achieves significant revenue or market capitalization milestones. This strategic alignment underscores a leadership philosophy focused on sustainable growth and value creation rather than short-term gains. Concurrently, BioLargo fortified its market position through the renewal of key contracts, including $1.4 million in Air Force agreements, and expanded its global footprint via strategic collaborations such as a memorandum with Aquatech and an exclusive distribution deal for ViaCLYR across the Middle East and North Africa, thereby securing stable revenue streams and enhancing its competitive edge.

BioLargo’s corporate strategy deliberately targets high-growth sectors, notably PFAS removal and anti-biofilm wound care, which are projected to expand at compound annual growth rates of 7.1% and 9.8% respectively. This diversification into cleantech and life sciences markets reflects a calculated effort to maximize both shareholder value and societal impact by addressing urgent environmental and healthcare challenges. By positioning itself within these rapidly evolving industries, BioLargo not only taps into lucrative opportunities but also aligns its innovation pipeline with global trends demanding sustainable and effective solutions.